

**KENNETH D. HATCH, MD**  
**PUBLICATIONS**

**PEER-REVIEWED PUBLICATIONS**

1. McGoogan LS, **Hatch KD**. Krukenberg tumor - Report of two cases. The Nebraska Medical Journal 1972;57:409-15.
2. **Hatch KD**, Shingleton HM, Austin Jr. JM, Boots LR, Younger B, Soong S-J. Southern regional trophoblastic disease center. So Med J 1978; 71:11.
3. Butterworth Jr. CE, **Hatch KD**, Austin Jr. JM, Mueller H. Foliate-induced regression of cervical dysplasia in users of oral contraceptive agents (OCA). Clinical Research 1978;26:677A.
4. Partridge EE, Beasley WE, Holcomb C, **Hatch KD**, Shingleton HM, Austin Jr. JM. The swan-ganz catheter and management of patients undergoing pelvic exenteration. Obstet Gynecol 1979;53(2):253.
5. **Hatch KD**. Gestational trophoblastic disease. JCE OB/GYN 1979;21:17-27.
6. Partridge EE, Murad T, Shingleton HM, Austin Jr. JM, **Hatch KD**. Verrucous lesions of the female genitalia. Am J Obstet Gynecol 1980;137(4):412-7.
7. Partridge EE, Murad T, Shingleton HM, Austin Jr. JM, **Hatch KD**. Verrucous lesions of the female genitalia II. Verrucous carcinoma. Am J Obstet Gynecol 1980;137(4):418-24.
8. Orr Jr. JW, Austin Jr. JM, **Hatch KD**, Shingleton HM, Younger JB, Boots LR. Acute pulmonary edema associated with molar pregnancies: a high risk factor for development of persistent throphoblastic disease. Am J Obstet Gynecol 1980;136(3):412-5.
9. **Hatch KD**, Shingleton HM, Younger JB, Boots LR. Elevated beta hCG titers in oophorectomized women being treated for trophoblastic disease. Am J Obstet Gynecol 1980;137(1):122-6.
10. Partridge EE, Shingleton HM, **Hatch KD**, Austin Jr. JM. Verrucous and condylomatous lesions of the female genitalia - a diagnostic dilemma: I - giant condyloma with and without squamous malignant change, II - verrucous carcinoma. Am J Obstet Gynecol 1980;137(4):412-8.
11. **Hatch KD**, Shingleton HM, Gore H, Younger JB, Boots LR. hCG secreting large cell carcinoma of the lung detected during follow up of a patient previously treated for gestational trophoblastic disease. Gynecol Oncol 1980;10(1):98-104.
12. **Hatch KD**, Mann WJ, Tauze WN, Buchina ES, Shingleton HM, Boots LR. Localization of choriocarcinoma by 131 I-beta hCG antibody. Gynecol Oncol 1980;10(3):253-61.

13. **Hatch KD**, Shingleton HM, Taylor PT, Austin Jr. JM, Younger JB, Boots LR. Trophoblastic disease in Alabama - influence of its regional center. *J Ala Med Assoc* 1980; 7-10.
14. Mann WJ, **Hatch KD**, Levy DS, Shingleton HM, Soong S-J. The prognostic significance of age in stage I carcinoma of the cervix. *So Med J* 1980;73(9):1186-8.
15. Mann WJ, Jander HP, Partridge EE, Russinovich N, **Hatch KD**, Taylor PT, Shingleton HM. Selective arterial embolization for control of bleeding in gynecologic malignancy. *Gynecol Oncol* 1980;10(3):279-89.
16. Mann WJ, Janer P, Orr Jr. JW, Taylor PT, **Hatch KD**, Shingleton HM. The use of percutaneous nephrostomy in gynecologic oncology. *Gynecol Oncol* 1980;10(3):343-9.
17. **Hatch KD**, Shingleton HM, Austin Jr. JM. Cryosurgery of intraepithelial neoplasia. *Obstet Gynecol* 1981;57(6):692-7.
18. Mann WJ, Orr Jr. JW, Shingleton HM, Austin Jr. JM, **Hatch KD**, Taylor PT, Partridge EE, Soong S-J. Perioperative influences on infectious morbidity in radical hysterectomy. *Gynecol Oncol* 1981;11(2):207-12.
19. Scott LK, Shingleton HM, **Hatch KD**, Maisiak R. Evaluation of the impact of a colposcopy satellite clinic. *So Med J* 1981;74(4):413.
20. Orr Jr. JW, Shingleton HM, Gore H, Austin Jr. JM, **Hatch KD**, Soong S-J. Cervical intraepithelial neoplasia associated with exposure to diethylstilbestrol (DES) in utero: a clinical and pathologic study. *Obstet Gynecol* 1981;58(1):75-82.
21. Orr Jr. JW, Shingleton HM, **Hatch KD**, Taylor PT, Mann WJ, Parham G, Austin Jr. JM, Partridge EE, Soong S-J, Clould G. Correlation of perioperative morbidity and conization-radical hysterectomy interval. *Obstet Gynecol* 1982;59(6):726-39.
22. Orr Jr. JW, Shingleton HM, **Hatch KD**, Taylor PT, Austin Jr. JM, Partridge EE, Soong S-J. Urinary diversion in patients undergoing pelvic exenteration. *Am J Obstet Gynecol* 1982;142(7):883-9.
23. Phillips JG, Orr Jr. JW, Grizzle W, **Hatch KD**, Shingleton HM. An adrenal pheochromocytoma mimicking lymph node metastasis from a cervical cancer - case report. *Gynecol Oncol* 1982;13(3):416-22.
24. Butterworth Jr. CE, **Hatch KD**, Gore H, Mueller H, Krumdieck CL. Improvement in cervical dysplasia associated with folic acid therapy in users of oral contraceptives. *Am J Clin Nutri* 1982;35:73-82.

25. Shingleton HM, Gore H, Soong S-J, **Hatch KD**, Orr Jr. JW, Austin Jr. JM. Tumor recurrence and survival in stage IB cancer of the cervix. *Am J Clin Oncol* 1983;6:265.
26. Orr Jr. JW, **Hatch KD**, Shingleton HM, Taylor PT, Partridge EE, Soong S-J. Gastrointestinal complications associated with pelvic exenteration. *Am J Obstet Gynecol* 1983;145(3):325-32.
27. Mann WJ, **Hatch KD**, Taylor PT, Partridge EE, Orr Jr. JW, Shingleton HM. The use of percutaneous nephrostomy in gynecologic oncology. *Gynecol Oncol* 1983;16(3):393-9.
28. Boots LR, **Hatch KD**, Younger JB. Laboratory assessment of disappearance patterns of human chorionic gonadotropin from serum patients with gestational trophoblastic disease. *Ala J Med Sciences* 1983;20(4):391-4.
29. Orr Jr. JW, Shingleton HM, Soong S-J, **Hatch KD**, Bryant JW, Partridge EE, Austin Jr. JM, Taylor PT. Hemodynamic parameters following pelvic exenteration. *Am J Obstet Gynecol* 1983;146(8):882-92.
30. Kim RY, Levy DS, Brascho DJ, **Hatch KD**. Uterine perforation during intracavitary application - Prognostic significance in carcinoma of the cervix. *Radiology* 1983;147(1):249-51.
31. **Hatch KD**. Construction of a neovagina following exenteration utilizing the vulvobulbocavernosus myocutaneous graft. *Obstet Gynecol* 1984;63(1):110-4.
32. Delgado G, Goldson AL, Ashayeri E, Hill LT, Petrilli ES, **Hatch KD**. Intraoperative radiation in the treatment of advanced cervical cancer. *Obstet Gynecol* 1984;63(2):246-52.
33. Kerr-Wilson RHJ, Shingleton HM, Orr Jr. JW, **Hatch KD**. The use of ultrasound and CT scanning in the management of gynecologic cancer patients. *Gynecol Oncol* 1984;18(1):54-61.
34. **Hatch KD**, Parham G, Shingleton HM, Austin Jr. JM, Orr Jr. JW. Ureteral strictures and fistulae following radical hysterectomy. *Gynecol Oncol* 1984;19(1):17-23.
35. Simon NL, Orr Jr. JW, **Hatch KD**, Shingleton HM. Lower extremity edema due to deep vein thrombosis in patients with recurrent cervix cancer. *Gynecol Oncol* 1984;19(1):30-3.
36. Kilgore LC, Orr Jr. JW, **Hatch KD**, Shingleton HM, Roberson J. Peritoneal cytology in patients with squamous cell carcinoma of the cervix. *Gynecol Oncol* 1984;19(1):24-30.

37. Conroy JF, Lewis Jr. GC, Blessing JA, Mangan C, **Hatch KD**, Wilbanks G. ICRF 159 (Razoxane) in patients with advanced squamous cell carcinoma of the uterine cervix (For the Gynecologic Oncology Group). *Am J Clin Oncol: Cancer Clinical Trials* 1984;7(2):131-3.
38. **Hatch KD**, Shingleton HM, Orr Jr. JW, Gore H, Soong S-J. The role of endocervical curettage in colposcopy. *Obstet Gynecol* 1985;65(3):403-8.
39. Orr Jr. JW, Wilson K, Bodiford C, Cornwell A, Soong S-J, Honea KL, **Hatch KD**, Shingleton HM. Nutritional status of patients with untreated cervical cancer. I. Biochemical and immunologic assessment. *Am J Obstet Gynecol* 1985;151(5):625-32.
40. Gauthier P, Gore I, Shingleton HM, Soong S-J, Orr Jr. JW, **Hatch KD**. Identification of histopathologic risk groups in stage IB squamous cell carcinoma of the cervix. *Obstet Gynecol* 1985;66(4):569-74.
41. Omura GA, Hubbard JL, **Hatch KD**. Chemotherapy of cervix cancer with doxorubicin and cisplatin: A phase I pilot study of the Gynecologic Oncology Group. *Am J Clin Oncol (CCT)* 1985;8(5):347-9.
42. Muss HB, Sutton GP, Bundy B, **Hatch KD**. Mitoxantrone (NSC 301739) in patients with advanced cervical carcinoma: A phase II study of the Gynecologic Oncology Group. *Am J Clin Oncol* 1985;8:312-5.
43. Kerr-Wilson RHJ, Orr Jr. JW, Shingleton HM, **Hatch KD**, Trammel MW. The effect of beta adrenergic stimulation on the bladder and urethra following radical hysterectomy. *Gynecol Oncol* 1986;23(3):267-74.
44. Simon NL, Gore H, Shingleton HM, Soong S-J, Orr Jr. JW, **Hatch KD**. Study of superficially invasive carcinoma of the cervix. *Obstet Gynecol* 1986;68(1):19-24.
45. Vance JC, Bart BJ, Hansen RC, Reichman RC, McEwen C, **Hatch KD**, Berman B, Tanner DJ. Intralesional recombinant Alpha-2 Interferon for the treatment of patients with condyloma acuminatum or verruca plantaris. *Archives of Dermatol* 1986;122(3):272-7.
46. Homesley HD, Blessing JA, Conroy J, **Hatch KD**, DiSaia PJ, Twiggs LB. ICRF-159 (Razoxane) in patients with advanced adenocarcinoma of the endometrium: A Gynecologic Oncology Group Study. GOG Manuscript for Protocol #26-G. *Am J Clin Oncol: Cancer Clinical Trials* 1986;9(1):15-7.
47. Barter JF, Orr Jr. JW, **Hatch KD**, Shingleton HM. Diethylstilbestrol in pregnancy: an update. *So Med J* 1986;79(12):1531-4.

48. Barter JF, **Hatch KD**, Orr Jr. JW, Shingleton HM. Isolated abdominal wound recurrence of an endometrial adenocarcinoma confined to a polyp. *Gynecol Oncol* 1986;25(3):372-5.
49. Alvarez RD, **Hatch KD**, Gore H. Papillary squamous cell tumors of the uterine cervix. *Cervix* 1986;4:133-8.
50. To ACW, Soong S-J, Shingleton HM, Gore H, Wilkerson JA, **Hatch KD**, Phillips D, Dollar JR. Immunohistochemistry of the blood group ABH isoantigens and Oxford Ca antigen as prognostic markers for stage IB squamous cell carcinoma of the cervix. *Cancer* 1986;58(11):2435-9.
51. Khazaeli MB, Hedayat MM, **Hatch KD**, To ACW, Soong S-J, Shingleton HM, Boots LR, LoBuglio AF. Radioimmunoassay of free B-subunit of hCG as a prognostic test for persistent trophoblastic disease in molar pregnancy. *Am J Obstet Gynecol* 1986;155(2):320-4.
52. To ACW, Gore H, Shingleton HM, Wilkerson JA, Soong S-J, **Hatch KD**. Lymph node metastasis in cancer of the cervix: A preliminary report. *Am J Obstet Gynecol* 1986;155(2):388-9.
53. Orr Jr. JW, Ball GC, Soong S-J, **Hatch KD**, Partridge EE, Austin Jr. JM. Surgical treatment of women found to have invasive cervical cancer at the time of total hysterectomy. *Obstet Gynecol* 1986;68(3):353-6.
54. McGuire WP, Blessing JA, **Hatch KD**, DiSaia PJ. A phase II study of CHIP in advanced squamous cell carcinoma of the cervix. (A Gynecologic Oncology Group Study). *Investigational New Drugs* 1986;4:181-6.
55. Orr Jr. JW, Barter JF, Kilgore LC, Soong S-J, Shingleton HM, **Hatch KD**. Closed suction pelvic drainage after radical pelvic surgical procedures. *Am J Obstet Gynecol* 1986;155(4):867-71.
56. **Hatch KD**, Kilgore LC, Austin Jr. JM, Partridge EE, Younger JB, Shingleton HM. Rectosigmoid resection and repair in the management of endometriosis. *Surgical Forum* 1986;36:467-9.
57. Thigpen JT, Blessing JA, Fowler Jr. WC, **Hatch KD**. Phase II trials of cisplatin and piperazinedione as single agents in the treatment of advanced or recurrent non-squamous carcinoma of the cervix: A Gynecologic Oncology Group Study. *Cancer Treatment Reports* 1986;70(9):1097-100.
58. Petrilli ES, Twiggs LB, Curry SL, Sikic B, **Hatch KD**, Schlaerth JB, Lessing J. Single-dose Actinomycin-D treatment for nonmetastatic gestational trophoblastic disease. *Gynecol Oncol* 1986;23:244.

59. Orr Jr. J, Ball C, Shingleton H, Soong S, **Hatch KD**, Partridge E, Austin J. Radical reoperation of women found to have invasive cervix cancer at the time of total hysterectomy. *Gynecol Oncol* 1986;23:257.
60. **Hatch KD**. Evaluation of Alpha-2 Interferon (SCH 30500) in the treatment of condyloma acuminatum. *J Reprod Med* 1986;31(10):979.
61. Cauda R, Tying SK, Grossi CE, Tilden AB, **Hatch KD**, Sams Jr. WM, Baron S, Whitley RJ. Patients with condyloma acuminatum exhibit decreased Interleukin 2 and Interferon Gamma production and depressed natural killer activity. *J Clin Immunology* 1987;7(4):304-11.
62. Barter JF, Orr Jr. JW, Holloway RW, **Hatch KD**, Shingleton HM. Psammoma bodies in a cervicovaginal smear associated with an intrauterine device. *J Reprod Med* 1987;32:147-8.
63. Alvarez RD, To ACW, Boots LR, Shingleton HM, **Hatch KD**, Hubbard JL, Soong S-J, Potter ME. CA125 as a serum marker for poor prognosis in ovarian malignancies. *Gynecol Oncol* 1987;26(3):284-9.
64. Farquharson DIM, Shingleton HM, Soong S-J, Sanford SP, Levy DS, **Hatch KD** with the Technical Assistance of Shirley Hester. The adverse effects of cervical cancer treatment on bladder function. *Gynecol Oncol* 1987;27(1):15-23.
65. Dollar JR, Orr Jr. JW, Shingleton HM, **Hatch KD**, Partridge EE, Soong S-J. Metastatic tumors mimicking gynecologic cancer. *Obstet Gynecol* 1987;69(6):865-7.
66. Barter JF, Soong S-J, **Hatch KD**, Austin Jr. JM, Orr Jr. JW, Partridge EE, Shingleton HM. Treatment of nonmetastatic gestational neoplasia with oral methotrexate. *Am J Obstet Gynecol* 1987;157(5):1166-8.
67. Farquharson DIM, Shingleton HM, Orr Jr. JW, **Hatch KD**, Varner RE, Soong S-J. The effect of radical hysterectomy on urethral and bladder neck function. *Br J Obstet Gynecol* 1987;94(4):351-7.
68. Barter JF, Mazur M, Holloway RW, **Hatch KD**. Melanosis of the cervix. *Gynecol Oncol* 1988;29(1):101-4.
69. Kutteh WH, **Hatch KD**, Blackwell RE, Mestecky J. Secretory immune system of the female reproductive tract: I. Immunoglobulin and secretory component-containing cells. *Obstet Gynecol* 1988;71(1):56-60.

70. Baker VV, Shingleton HM, **Hatch KD**, Miller DM. Selective inhibition of c-MYC expression by the RNA synthesis inhibitor, Mithramycin. *Am J Obstet Gynecol* 1988;158(4):762-7.
71. Butterworth Jr. CE, **Hatch KD**, Cole P, Sauberlich HE, Tamura T, Cornwell PE, Soong S-J. Zinc concentration in plasma and erythrocytes of subjects receiving folic acid supplementation. *Am J Clin Nutr* 1988;47:484-6.
72. **Hatch KD**, Shingleton HM, Potter ME, Baker VV. Low rectal resection and anastomosis at the time of pelvic exenteration. *Gynecol Oncol* 1988;31(2):262-7.
73. **Hatch KD**, Shingleton HM, Soong S-J, Baker VV, Gelder MS. Anterior pelvic exenteration. *Gynecol Oncol* 1988;31(1):205-16.
74. Kilgore LC, Soong S-J, Gore H, Shingleton HM, **Hatch KD**, Partridge EE. Analysis of prognostic features in adenocarcinoma of the cervix. *Gynecol Oncol* 1988;31(1):137-53.
75. **Hatch KD**, Bart BJ, Hansen RC, Millikan LE, Reichman RC, Berman B. Evaluation of Interferon Alpha-2 (SCH 30500) in the treatment of condyloma acuminatum. *Colposcopy and Gynecol Laser Surg* 1988;4(3):187-96.
76. Baker VV, Allen DN, **Hatch KD**, Shingleton HM. C-myc proto-oncogene amplification and prognosis in carcinoma of the uterine cervix. *J Surg Oncol* 1988;39(4):225-8.
77. Barter JF, Soong S-J, Shingleton HM, **Hatch KD**, Orr Jr. JW: Complications of combined radical hysterectomy-postoperative radiation therapy in women with early stage cervical cancer. *Gynecol Oncol* 1989;32(3):292-6.
78. Potter ME, Partridge EE, Shingleton HM, Soong S-J, Kim RY, **Hatch KD**, Austin Jr. JM. Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits. *Gynecol Oncol* 1989;32(3):314-8.
79. Thigpen JT, Blessing JA, DiSaia PJ, Fowler Jr. WC, **Hatch KD**. A randomized comparison of a rapid versus prolonged (24 hour) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: A Gynecologic Oncology Group Study. *Gynecol Oncol* 1989;32(5):198-202.
80. Khazaeli MB, Buchina ES, Pattillo RA, Soong S-J, **Hatch KD**. Radioimmunoassay of free B-subunit of human chorionic gonadotropin in diagnosis of high-risk and low-risk gestational trophoblastic disease. *Am J Obstet Gynecol* 1989;160(2):444-9.
81. Barter JF, Soong S-J, **Hatch KD**, Orr Jr. JW, Partridge EC, Austin Jr. JM, Shingleton HM. Treatment of nonmetastatic gestational trophoblastic disease with sequential intramuscular and oral methotrexate. *Gynecol Oncol* 1989;33(1):82-4.

82. Potter ME, **Hatch KD**, Potter MY, Shingleton HM, Baker VV. Factors affecting the response of recurrent squamous cell carcinoma of the cervix to Cisplatin. *Cancer* 1989;63:1283-6.
83. Potter ME, Moradi M, To ACW, **Hatch KD**, Shingleton HM. The value of serum CA125 levels: Does the result preclude second look? *Gynecol Oncol* 1989;33(2):201-3.
84. Shingleton HM, Soong S-J, Gelder MS, **Hatch KD**, Baker VV, Austin Jr. JM. Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix. *Obstet Gynecol* 1989;73(6):1027-34.
85. Baker VV, **Hatch KD**, Shingleton HM. Neurofibrosarcoma complicating pregnancy. *Gynecol Oncol* 1989;34:237-9.
86. McGuire WP, Arseneau J, Blessing JA, DiSaia PJ, **Hatch KD**, Given FT, Teng NNH, Creasman WT. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: A Gynecologic Oncology Group Study. *J Clin Oncol* 1989;7(10):1462-8.
87. Santa Cassia LJ, Weppelmann B, Shingleton HM, Soong S-J, **Hatch KD**. Management of early endometrial carcinoma. *Gynecol Oncol* 1989;35(3):362-6.
88. Potter ME, Alvarez RD, Gay FL, Shingleton HM, Soong S-J, **Hatch KD**. The optimal therapy for pelvic recurrence after radical hysterectomy for early stage cervical cancer. *Gynecol Oncol* 1990;37(1):74-7.
89. Potter ME, Alvarez RD, Shingleton HM, Soong S-J, **Hatch KD**. Early invasive cervical cancer with pelvic lymph node involvement: To complete or not to complete radical hysterectomy? *Gynecol Oncol* 1990;37(1):78-81.
90. Muss HB, Blessing JA, **Hatch KD**, Soper JT, Webster KD, Kemp GM. Methotrexate in advanced endometrial carcinoma: A Phase II trial of the Gynecologic Oncology Group. *Am J Clin Oncol* 1990;13(1):61-3.
91. Tamura T, Soong S-J, Sauberlich HE, **Hatch KD**, Cole P, Butterworth CE. Evaluation of the deoxyuridine suppression test using whole blood samples from folic acid-supplemented subjects. *Am J Clin Nutr* 1990;51(1):80-6.
92. **Hatch KD**, Gelder MS, Soong S-J, Baker VV, Shingleton HM. Pelvic exenteration with low rectal anastomosis: survival, complications, and prognostic factors. *Gynecol Oncol* 1990;38:462-7.



93. Morgan JM, Alvarez RD, **Hatch KD**. Delayed split-thickness skin grafting after radical excision in the treatment of advanced hidradenitis suppurativa of the vulva and perianus. *J Gynecol Surg* 1990;6(2):129-34.
94. Baker V, Borst M, Dixon D, **Hatch KD**, Shingleton H, Miller D. c-MYC amplification in ovarian cancer. *Gynecol Oncol* 1990;38:340-2.
95. Barter J, Soong S-J, **Hatch KD**, Orr J, Shingleton H. Diagnosis and treatment of pulmonary metastases from cervical carcinoma. *Gynecol Oncol* 1990;38:347-51.
96. Borst M, Baker V, Dixon D, **Hatch KD**, Shingleton H, Miller D. Oncogene alterations in endometrial carcinoma. *Gynecol Oncol* 1990;38:364-6.
97. **Hatch, KD**. Implications of human papillomavirus in cervical and vulvar cancer. *Current Opinion in Obstet and Gynecol*. 1990;2:80-4.
98. Potter ME, Partridge EE, **Hatch KD**, Soong S-J, Austin JM, Shingleton HM. The primary surgical therapy of ovarian cancer: How much, by whom and when. *Gynecol Oncol* 1991;40:195-200.
99. Borst M, Baker V, Kuykendall K, Gore H, **Hatch KD**. Human papillomavirus screening for women with atypical papanicolau smears. *J Reprod Med* 1991;36(2) 95-9.
100. **Hatch KD**. Vulvovaginal human papillomavirus infections: Clinical implications and management. *Am J Obstet and Gynecol* 1991;165:1183-8.
101. Williams SD, Blessing JA, **Hatch KD**, Homesley HD. Chemotherapy of advanced dysgerminoma: Trials of the Gynecologic Oncology Group. *J Clin Oncol* 1991; 9(11):1950-5.
102. Alvarez RD, Potter ME, Soong S-J, Gay FL, **Hatch KD**, Partridge EE, Shingleton HM. Rationale for using pathologic tumor dimensions and nodal status to subclassify surgically treated Stage IB cervical cancer patients. *Gynecol Oncol* 1991;43:108-12.
103. **Hatch KD**, Beecham JB, Blessing JA, Creasman WT. Tamoxifen responsiveness in patients with advanced ovarian carcinoma: A Gynecologic Oncology Group study of second-line therapy in 105 patients. *Cancer* 1991;68:269-71.
104. Butterworth CE, **Hatch KD**, Cole P, Sauberlich HE, Soong S-J, Baker VV, Macaluso M. Folate deficiency and cervical dysplasia. *JAMA* 1992;267(4):528-33.
105. Kutteh WH, **Hatch KD**. Primary vaginal tuberculosis after radiation therapy for vaginal carcinoma. *Gynecol Oncol* 1992;44:113-5.
106. **Hatch KD**. Cervical cancer in the young patient. *Gynecol Oncol* 1992;44:121-2.

107. Butterworth CE, **Hatch KD**, Soong S-J, Cole P, Tamura T, Sauberlich H, Borst M, Macaluso M, Baker VV. Oral folic acid supplementation for cervical dysplasia: A clinical intervention trial. *Am J Obstet Gynecol* 1992;166(3):803-9.
108. Helm CW, **Hatch KD**, Austin JM, Partridge EE, Soong S-J, Elder JE, Shingleton HM. A matched comparison of single and triple incision techniques for the surgical treatment of carcinoma of the vulva. *Gynecol Oncol* 1992;46:150-6.
109. Gordon P, **Hatch KD**. Survey of colposcopy practices by obstetrician/gynecologists. *J Reprod Med* 1992;37(10):861-63.
110. Sutton G, Soper J, Blessing J, **Hatch KD**, Barnhill D. Ifosfamide alone and in combination in the treatment of refractory malignant gestational trophoblastic disease. *Am J Obstet and Gynecol* 1992;167(2):489-95.
111. **Hatch KD**. Vulvar and vaginal disorders. *Cur Sci* 1992;904-6.
112. Childers JM, **Hatch KD**, Surwit EA. Office laparoscopy and biopsy for evaluation of patients with intraperitoneal carcinomatosis using a new optical catheter. *Gynecol Oncol* 1992;47:337-42.
113. **Hatch, KD**. Neovaginal reconstruction. *Cancer*, 1993;71:1660-3
114. Helm CW, **Hatch KD**, Partridge EE, Shingleton HM. The Rhomboid Transposition Flap for Repair of the Perineal Defect after Radical Vulvar Surgery. *Gynecol Oncol* 1993;50:164-7.
115. Potter, ME, Spencer S, Soong S-J, **Hatch, KD**. The Influence of Staging Laparotomy for Cervical Cancer on Patterns of Recurrence and Survival. *Int J Gynecol Cancer* 1993;3:169-74.
116. Childers JM, Brzechffa PR, **Hatch KD**, Surwit EA. Surgical Staging of patients with Clinical Stage I Endometrial Carcinoma, including Lymphadenectomy and Hysterectomy, is shown to be a safe, attractive alternative to the traditional approach. *Gynecol Oncol* 1993;51:33-8.
117. Childers JM, **Hatch KD**, Tran A-N, Surwit, EA. Laparoscopic Para-Aortic Lymphadenectomy in Gynecologic Malignancies. *Obstet Gynecol* 1993;82:741-7.
118. Schneider V, Schneider A, Reed K, **Hatch KD**. Comparison of Doppler with Two-Dimensional Sonography and CA 125 for Prediction of Malignancy of Pelvic Masses. *Obstet Gynecol* 1993;81:983-8.

119. **Hatch KD.** Colposcopy of Vaginal and Vulvar Human Papillomavirus and Adjacent Sites. *Obstet and Gynec. Clinics of No America* 1993;20(1).
120. **Hatch KD.** Preinvasive Cervical Neoplasia. *Seminars in Oncology.* 1994;21:12-6.
121. Childers JM, Aqua KA, Surwit EA, Hallum AV, **Hatch KD.** Abdominal-Wall Tumor Implantation after Laparoscopy for Malignant Conditions. *Obstet and Gynecol* 1994;84(5).
122. Kim YI, Mason JB, Guiliano A, Nour MA, Selhub J, **Hatch KD,** Schneider A, Rosenberg IH. Global DNA Hypomethylation increases progressively in cervical dysplasia and carcinoma. *Cancer* 1994;74:893-9.
123. **Hatch KD.** Clinical appearance and treatment strategies for human papillomavirus: A Gynecologic Perspective. *Am. J. Obstet and Gynecol* 1995;172:1340-4.
124. **Hatch KD,** Schneider A, Nour M. An evaluation of Human Papillomavirus Testing for Intermediate and High-Risk Types as Triage Prior to Colposcopy. *Am. J. Obstet and Gynecol* 1995;1150-5.
125. Hallum AV, Alberts DS, Lippman SM, Inclan L, Shamdas GJ, Childers JM, Surwit EA, Modiano M, **Hatch KD.** Phase II Study of 13-*cis*-Retinoic Acid plus Interferon- $\alpha_{2a}$  in Heavily Pretreated Squamous Carcinoma of the Cervix<sup>1</sup>. *Gyn Onc* 1995;56:382-5.
126. Atlas I, Hallum AV, **Hatch KD.** Laparoscopic Repair of Vaginal Gore-Tex Erosion after Sacral Colpopexy. *J. Gynecol Surg* 1995;11:177.
127. **Hatch, KD.** Cryotherapy. *Balliere's Clin. Obstet and Gynecol* 1995;9(1):133-43.
128. Schnorr JA, Miller H, Davis JR, **Hatch KD,** Seeds J. Hyperreactio Luteinalis Associated with Pregnancy: A Case Report and Review of the Literature. *Am. J. Perinatol* 1996;113(2).
129. Childers JM, Lang J, Surwit EA, **Hatch KD.** Laparoscopic Surgical Staging of Ovarian Cancer. *Gyn Oncol.* 1996;59:25-33.
130. **Hatch KD,** Hallum AV, Surwit EA, Childers JM. The Role of Laparoscopy in Gynecologic Oncology. *Cancer* 1996;76:2113-6.
131. Surwit E, Childers J, Atlas I, Nour M, **Hatch K,** Hallum A, Alberts D. Neoadjuvant Chemotherapy for Advanced Ovarian Cancer. *Int'l J Gyn Cancer* 1996;6(5):356-61.
132. **Hatch KD,** Hallum AV, Nour M. New Surgical Approaches to Treatment of Cervical Cancer. *J of the National Cancer Institute Monographs* 1996;21:71-5.

133. Markman M, Iseminger KA, **Hatch KD**, Creasman WT, Barnes W, Dubeshter B. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. *Gynecol Oncol* 1996;62(1):4-6.
134. Hallum AV, **Hatch KD**, Baker V, Nour M. Panniculectomy Combined with Major Pelvic Surgery in Morbidly Obese Women with Gynecological Cancer. *J. Gynecol Tech* 1997;3:9-16.
135. **Hatch KD**. Electrosurgical Excision Procedures: LLETZ and LEEP-A Critical Analysis. *J. Lower Genital Tract Disease* 1997;1(2):107-10.
136. **Hatch KD**. What works. Telemedicine links specialists with rural Iowans. *Health Management Technology* 1997;18(10):32.
137. Guiliano AR, Papenfuss M, Nour M, Canfield LM, Schneider A, **Hatch KD**. Antioxidant nutrients: associations with persistent human papillomavirus infection. *Cancer Epidemiology: Biomarkers and Prevention* 1997;6(11):917-23.
138. Creasman WT, Zaino RJ, Major FJ, DiSaia PJ, **Hatch KD**, Homesley HD. Early invasive carcinoma of the cervix (3 to 5 mm invasion): Risk Factors and prognosis. A Gynecologic Oncology Group Study. *Am J. Obstet Gynecol* 1998;178:62-5.
139. **Hatch KD**. EDITORIAL: The Role of Operative laparoscopy to evaluate candidates for pelvic exenteration. *Gynecol Oncol* 1998;69(2):93.
140. Monk BJ, Alberts DS, Burger RA, Fanta PT, Hallum AV, **Hatch KD**, Salmon SE. *In Vitro* Phase II Comparison of the Cytotoxicity of a Novel Platinum Analog, Nedaplatin (254-S), with That of Cisplatin and Carboplatin against Fresh, Human Cervical Cancers. *Gyn Onc* 1998;71:308-12.
141. Fowler, BM, Guiliano AR, Piyathilake C, Nour M, **Hatch KD**. Hypomethylation in Cervical Tissue: Is there a Correlation with Folate Status? *Cancer Epidemiology: Biomarkers and Prevention* 1998 pp901-6.
142. Peng YM, Peng YS, Childers JM, **Hatch KD**, Roe DJ, Lin Y, Lin P. Concentrations of carotenoids, tocopherols, and retinol in paired plasma and cervical tissue of patients with cervical cancer, precancer, and noncancerous diseases. *Cancer Epidemiolo Biomarkers Prev* 1998;7(4):347-50.
143. Trizna Z, Evans T, Bruce S, **Hatch KD**, Tyring SK. A randomized phase II study comparing four different interferon therapies in patients with recalcitrant condylomata acumniata. *Sexually Transmitted Diseases* 1998;25(7):361-5.
144. **Hatch KD**. Low Rectal Anastomosis Following Pelvic Exenteration. *Nogyogyaszati Onkologia* 1998;2:147-50.

145. Giuliano AR, Papenfuss M, Schneider A, Nour M, **Hatch KD**. Risk factors for high-risk type human papillomavirus infection among Mexican-American women. *Cancer Epidemiology, Biomarkers & Prevention* 1999;8(7):615-20.
146. Babin EA, Davis JR, **Hatch KD**, Hallum AV. Wilms' Tumor of the Cervix: A Case Report and Review of the Literature. *Gyn Onc.* 2000;76(1):107-11.
147. **Hatch KD**, Hallum A, Nour M, Saucedo M. Comparison of Radical Abdominal Hysterectomy with Laparoscopic Assisted Radical Vaginal Hysterectomy for Treatment of Early Cervical Cancer. *J. Gyn Techniques* 2000;6(1):3-6.
148. **Hatch KD**. Multisite Clinical Outcome Trial to Evaluate Performance of the ThinPrep Pap Test Tues. Posters 2000;95(4).
149. Garcia F, Giuliano A, **Hatch KD**, Baldwin S, Mendez E, Denman C, Gurnsey J, Papenfuss M, Stephens J, Abramson M. Preliminary results of the Binational Human Papillomavirus Study. *J. Lower Gen Tract Disease* 2000;4(3):138-9.
150. Jones, CM, **Hatch KD**, Harrigill K. Unilateral and Bilateral Sacrospinous Ligament Fixation for Pelvic Prolapse. *J. Pelvic Surg* 2001;7(1):27-33.
151. Inhorn SL, Wand PJ, Wright TC, **Hatch KD**, Hallum J, Lentricchia BB. Chlamydia trachomatis and Pap Testing from a Single, Fluid-Based Sample. A Multicenter Study. *J. Reprod. Medicine* 2001;46(3):237-42.
152. **Hatch KD**. Technique of Schauta Hysterectomy and Laparoscopic lymphadenectomy. *CME Journal of Gynecol Oncol* 2001;6(1):110-6.
153. Garcia F, Davis JR, Alberts DS, **Hatch KD**, Weyn B, Thompson D, Bartels PH. Nuclear chromatin patterns in normal, hyperplastic and atypical endometrium. *Anal Quant Cytol Histol* 2001;23(2):144-50.
154. Barker B, Garcia F, Lozevski J, Warner J, **Hatch KD**. The Correlation between Colposcopically Directed Cervical Biopsy and Loop Electrosurgical Excision Procedure Pathology and the Effect of Time on That Agreement. *Gyn Onc* 2001;82:22-6.
155. Giuliano AR, Papenfuss M, Abrahamsen M, Denman C, deZapien JG, Henze JLN, Ortega L, de Galaz EMB, Stephan J, Feng J, Baldwin S, Garcia F, **Hatch KD**. Human Papillomavirus Infection at the US-Mexico Border: Implications for Cervical Cancer Prevention and Control. *Cancer Epidemiol Biomarkers Prev* 2001;10(11):1129-36.
156. Barker B, Garcia F, Warner J, Lozevski J, **Hatch K**. The correlation between colposcopically directed cervical biopsy and Loop Electrosurgical Excision Procedure pathology and the effect of time on that agreement. *Gynecol Oncol* 2001;82:22-6.

157. Giuliano AR, Denman C, Guernsey de Zapien J, Navarro Henze JL, Orgeta L, Djambazov B, Mendez Brown de Galaz E, **Hatch KD**. Design and results of the ISA-Mexico border human papillomavirus (HPV), cervical dysplasia, and Chlamydia trachomatis study. *Pan American Journal of Public Health*. 2001;9(3):172-81.
158. Garcia F, Davis JR, **Hatch KD**, Alberts DS, Thompson D, Bartels P. Karyometry in endometrial adenocarcinoma of different grades. *Anal Quant Cytol Histol* 2002;24:93-102.
159. Barker B, Garcia F, Warner J, Lozevski J, **Hatch KD**. Baseline inaccuracy rates for the comparison of cervical biopsy to loop electrosurgical excision histopathologic diagnoses. *Am J Obstet Gynecol* 2002; 187(2):349-352.
160. Coleman RL, Mahoney NM, **Hatch KD**. Laparoscopic management of urolithiasis in a continent urostomy. *Gynecologic Oncology* 2002;84(3):473-8.
161. Giuliano AR, Harris R, Sedjo RL, Baldwin S, Roe D, Papenfuss MR, Abrahamsen M, Inserra P, Olvera S, **Hatch KD**. Incidence, prevalence and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. *Journal of Infectious Diseases* 2002;186(4):462-9.
162. Giuliano AR, Papenfuss M, Mendez Brown de Galaz E, Feng J, Abrahamsen M, Denman C, Guernsey de Zapien J, Navarro Henze JL, Garcia F, **Hatch KD**. Risk-factors for squamous intraepithelial lesions (SIL) of the cervix among women residing at the US-Mexico border. *Int J Cancer* 2003;109(1):112-8.
163. Garcia F, Barker B, Davis J, Schalk N, Shelton TJ, Meyer J, Harrigill K, **Hatch KD**. Thin-layer cytology and histopathology in the evaluation of abnormal uterine bleeding. *J Reprod Med* 2003;48:882-8.
164. Garcia F, Mendez E, Baldwin S, Papenfuss M, Giuliano AR, **Hatch KD**. Factors affecting the quality of cytologic cervical cancer screening along the Mexico-US border. *Am J Obstet Gynecol* 2003;189(2):467-472.
165. **Hatch K**. Low Rectal Anastomosis Following Pelvic Exenteration. *CME Journal of Gynecol Oncol*. Vol. 8, No. 3, pp. November 2003; 267-271.
166. Markman M, Glass T, Smith HO, **Hatch K**, Weiss G, Taylor S, Goodwill W, Alberts D. Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancer: a Southwest Oncology Group Trial. *Gynecol Oncol* 2003; 88(3): 282-8.

167. Sedjo R, Fowler B, Schnieder A, Henning S, **Hatch K**, Guiliano AR. Folate, vitamin B12 and homocysteine status: Findings of no relation between HPV persistence and cervical dysplasia. *Nutrition* 2003; 19(6):497-502.
168. **Hatch KD**. Laparoscopic lymphadenectomy and laparoscopic-assisted vaginal hysterectomy. *Gynecol Oncol* 2003; 90(3):503-504.
169. Garcia F, Ranger-Moore J, Barker B, Davis J, Brewer M, Lozevski J, Vinyak S, Liu Y, Yemane J, **Hatch KD**, Alberts DS, Bartels HG, Bartels PH. Karyometric image analysis for intraepithelial and invasive cervical lesions. *Anal Quant Cytol Histol* 2004; 26(3):141-50.
170. **Hatch KD**. Multi-centered direct to vial evaluation of liquid base pap smear. *J Low Genital Tract Dis* 2004;8(5):401-6.
171. Wright TC, Schiffman M, Solomon D, Cox TJ, Garcia F, Goldie S, **Hatch KD**, Noller KL, Roach N, Runowicz C, Saslow D. Interim guidance for the use of Human Papillomavirus DNA testing as an adjunct to cervical cytology for screening. *Obstet Gynecol* 2004; 103:304-9.
172. Fleisch MC, **Hatch KD**. Laparoscopic assisted parametrectomy/upper vaginectomy (LPUV)—technique, applications and results. *Gynecol Oncol* 2005; 98(3):420-426.
173. Im SS, Gordon AN, Buttin BM, Leath CA 3rd, Gostout BS, Shah C, **Hatch KD**, et al. Validation of referral guidelines for women with pelvic masses. *Obstet Gynecol* 2005; 105(1):35-41.
174. Brewer MA, Kirkpatrick ND, Wharton JT, Wang J, **Hatch KD**, et al. 4-HPR modulates gene expression in ovarian cells. *Int J Cancer* 2006; 119(5):1003-1013. **Hatch KD**. Retroperitoneal space. *Ob Gyn Management*, August 2006.
175. **Hatch KD**. The retroperitoneal space. *Ob Gyn Management*, August 2006, 18(8) p 16.
176. **Hatch KD**. Chapter 4, Clinical manifestations of HPV infection. Section A: Benign manifestations of HPV infection. A1. Anogenital condylomas. *Int J Gyn Ob* 2006, 94 (Suppl 1) S32-35.
177. **Hatch KD**. A2. Vulval intraperitoneal neoplasia (VIN). *Int J Gyn Ob* 2006, 94 (Suppl 1) S36-39.
178. **Hatch KD**. A3. Vaginal intraepithelial neoplasia (VAIN). *Int J Gyn Ob* 2006, 94 (Suppl 1) S40-43.

179. Fleisch MC, Newton J, Steinmetz In, Whitehair J, Hallum A, and **Hatch KD**. Learning and teaching laparoscopic advanced laparoscopic procedures: Do alternating trainees impair a laparoscopic surgeon's learning curve? *J Minmal Inv Gynecol* 2007; 14(3):293-299.
180. **Hatch KD**, Davis JR. Complete Resolution of Paget's Disease of the Vulva with Imiquimod Cream. *J Lower Genital Tract Dis* 2008; 12(2).90-94.
181. Zou C, Liu H, Feugang J, Hao Z, Alberts DS, **Hatch K**, Garcia, F: Green tea compound in chemoprevention of cervical cancer. *Gyn Oncol*, 2007; Submitted.
182. Tanbakuchi AA, Rouse AR, Gmitro AF, **Hatch KD**. A clinical confocal laparoscope for real-time in vivo optical biopsies. Submitted to the *Journal of Biomedical Optics* in 2009.
183. Tanbakuchi, AA, Rouse, AR, Udovich, JA, **Hatch, KD**, Gmitro, AF. In vivo imaging of ovarian tissue using a novel confocal microlaparoscope. Submitted to the *American Journal of Obstetrics and Gynecology* in 2009.
184. Addis, IB, **Hatch KD**, Berek JS, Intraepithelial Disease of the Cervix, Vagina, and Vulva.
185. **Hatch KD**, Berek JS, Pelvic Exenteration. In: Berek JS, Hacker NF, eds. *Berek and Hacker's Gynecologic Oncology, Fifth Edition*. Philadelphia: Lippincott Williams & Wilkins, 22: 2010.
186. **Hatch KD**, Berek JS, Laparoscopic Surgery. In: Berek JS, Hacker NF, eds. *Berek and Hacker's Gynecologic Oncology, Fifth Edition*. Philadelphia: Lippincott Williams & Wilkins, 22: 2010.

#### **Non-peer Reviewed Publications**

1. **Hatch KD**: Vulvovaginitis, practical management pointers for an embarrassing problem. *Consultant* 1982;23(3).
2. **Hatch KD**: Disease of the vulva. *O/GYN Clinics* 1982;1(1).
3. Shingleton HM, **Hatch KD**, Orr Jr. JW, Gore H, Soong S-J: Diagnosis and treatment of preinvasive and microscopically invasive squamous cell carcinoma of the cervix: including comments on surveillance of DES exposed patients with cytologic atypias. *The Cancer Bulletin* 1983;35(4):172-83.
4. **Hatch KD**: Carcinoma in situ of the vulva. *Continuing Education for the Family Physician*. 1983;18(8):745-49.



5. Mann WJ, **Hatch KD**: Managing ovarian germ cell tumors. Contemporary OB/GYN 1983;21(4):133-42.
6. Blackwell RE, Orr Jr. JW, Grizzle W, **Hatch KD**. The evaluation of a pelvic mass in a patient with a congenital malformation of the reproductive tract. The Female Patient 1984;9(1):33-4.
7. **Hatch KD**. Evaluation of condylomatous changes. Collected Letters 1984;25(8):60-2.
8. **Hatch KD**. Radical gynecologic surgery: The latest reconstructive techniques. Masters in Obstet and Gynecol 1985;1(1):20-4.
9. **Hatch KD**. Commentary on the role of Alpha Interferons in the treatment of condyloma acuminata. Interferon Letter 1986;3(1).
10. Baker VV, **Hatch KD**. Gynecologic surgery in the obese patient. Contemporary OB/GYN 1987;30(3):119-29.
11. **Hatch KD**, Holloway RW. Unilateral obstruction of the ureter by a pelvic mass. Clinical Decisions in Obstet Gynecol 1987;1(1):11-2.
12. Ferenczy A, **Hatch KD**, Popkin D, Roy M. Treating condylomata. Contemporary OB/GYN 1987;30(3):158-77.
13. Berek JS, Hacker NF, **Hatch KD**, Young RC: Uterine corpus and cervical cancer. Current Problems in Cancer 1988;12(2):61-131.
14. **Hatch KD**. Endometrial adenocarcinoma: Is pelvic and para-aortic lymph node biopsy necessary? Clinical Decisions in Obstet Gynecol 1988;2(3)9-10.
15. **Hatch KD**. Treatment of Human Papillomavirus. Obstetrics/Gynecology Report 1989;1(2):192-200.
16. **Hatch KD**. Interferon treatment of human papillomavirus. The Colposcopist (ASCCP publication) 1989;21(2):1-4.
17. **Hatch KD**. Implications of HPV infection in cervical and vulvar cancer. Current Opinion in Obstet Gynecol 1990;2:80-4.
18. **Hatch KD**. Laparoscopic lymph node dissection and radical hysterectomy. Up To Date (Web based learning).
19. **Hatch KD**. Retroperitoneal space. OB/GYN Management 2004.
20. **Hatch KD**. Guidelines for cervical cytology testing. OB/GYN Special Edition 2004;7.

21. **Hatch KD.** Response 1, Clinical Question: Ask the Experts. Management of Cervical Intraepithelial Neoplasia 2 in an Adolescent. *Journal of Lower Genital Tract Disease* 2004 8(20):156-7.
22. **Hatch KD.** Veritas Collagen Matrix in Complex Abdominal Wall Reconstruction. Clinical Review Monograph, Synovis Surgical Innovations, St. Paul, MN, Jan. 2007.

#### **CONTRIBUTIONS TO BOOKS**

1. **Hatch KD,** Shingleton HM, Gore H. Outpatient diagnosis and selection of treatment of cervical intraepithelial neoplasia using colposcopy. Hafex ESE, Smith JP (eds.) *Carcinoma of the Cervix.* The Hague/Boston/London: Martinus Nijhoff; 1982. pp 195-9.
2. **Hatch KD.** Detection and prevention of cervical cancer. McCarthy P (ed.) *American Academy of Family Practice Annual.* Parkrow Publisher; 1984.
3. **Hatch KD.** Cervical cancer. Berek JS, Hacker NF (eds.) *Practical Gynecologic Oncology.* Williams and Wilkins 1989. pp 241-83.
4. **Hatch KD,** Shingleton HM. Reconstructive surgery of the vulva and vagina. Gusberg SB, Shingleton HM, Deppe G (eds.) *Female Genital Cancer.* Church Livingstone Inc.
5. **Hatch KD.** Handbook of Colposcopy: Diagnosis and Treatment of Lower Genital Tract Neoplasia and HPV Infections. Little, Brown and Company; 1989.
6. **Hatch KD.** Urinary Tract Injury and Fistula. *Copeland's Textbook of Gynecology:* WB Saunders Company; 1993.
7. **Hatch KD.** Cryotherapy. *Bailliere's Clinical Obstetrics and Gynecology;* 1994.
8. **Hatch KD.** Exenterative Surgery of the Female Pelvis. *Gynecologic Oncology.* Churchill Livingstone, Inc.; 1994.
9. **Hatch KD.** Cervical Cancer. Berek/Hacker 2nd Edition, *Practical Gynecologic Oncology.* Williams and Wilkins; 1994, pp. 243-83.
10. **Hatch KD.** Complications of Surgery in the Treatment of Cervical Cancer. *Cervical Cancer and Preinvasive Neoplasia.* Lippincott-Raven Publishers, Inc.; 1996.
11. **Hatch KD.** Excisional Biopsy of Vulva/Vagina. *Gynecologic Oncology.* Churchill Livingstone, Inc.; 1996.

12. **Hatch KD**, Hacker NF. Intraepithelial Disease of the Cervix, Vagina and Vulva. Novak's GYNECOLOGY, 12th Edition. Williams and Wilkins; 1996.
13. **Hatch KD**, Fu, YS. Cervical and Vaginal Cancer. Novak's GYNECOLOGY, Twelfth Edition. Williams and Wilkins; 1996.
14. **Hatch KD**. Laparoscopy. Practical Gynecologic Oncology, Third Edition. Lippincott Williams and Wilkins; 2000.
15. **Hatch KD**. Pelvic Exenteration. Practical Gynecologic Oncology, Third Edition. Lippincott Williams and Wilkins; 2000.
15. **Hatch KD**, Hacker NF. Intraepithelial Disease of the Cervix, Vagina and Vulva. Novak's GYNECOLOGY, 13th Edition. Williams and Wilkins; 2001.
16. **Hatch KD**. Intraepithelial Disease of the Cervix, Vagina, and Vulva. Novak's GYNECOLOGY, Thirteenth Edition. Lippincott Williams and Wilkins; 2002.
17. **Hatch KD**. Laparoscopic Pelvic and Paraaortic Lymphadenectomy. In: UpToDate, Rose, BD (ed), UpToDate. Wellesley, MA; 2003.
18. **Hatch KD**. Laparoscopy in Practical Gynecology Oncology, Fourth Edition (Berek JS and Hacker NF, Eds). Lippincott Williams and Wilkins, Philadelphia, 2005.
19. **Hatch KD**, Berek JS. Pelvic Extenteration in Practical Gynecology Oncology, Fourth Edition (Berek JS and Hacker NF, Eds). Lippincott Williams and Wilkins, Philadelphia, 2005.
20. **Hatch KD**, Zoe C. Gynecologic Laparoscopic Surgery (in English and Chinese). Chinese Higher Education Press, China. September 2006.
21. **Hatch KD**. Radical Vaginal Hysterectomy and Laparoscopic Lymphadenectomy in Advances in Reconstructive Vaginal Surgery (Kovac SR and Zimmerman CW, Eds). Lippincott Williams & Wilkins, Philadelphia, 2007.
22. **Addis IB, Hatch KD, Berek JS**, Intraepithelial Disease of the Cervix, Vagina, and Vulva in Gynecology (Berek JS and Hacker NF, Eds). Lippincott Williams & Wilkins, Philadelphia, 2007.

## ABSTRACTS

1. Conroy J, Blessing J, Lewis G, Mangan C, **Hatch KD**, Wilbanks G. Phase II trial of ICRF-159 patients in treatment of advanced squamous cell carcinoma of the cervix. For the Gynecologic Oncology Group. Presented at the ASCO Meeting, San Diego, CA. March, 1980.
2. Davis ML, Orr Jr. JW, Soong S-J, Shingleton HM, Levy DS, Brascho DJ, **Hatch KD**, Partridge EE. Influence of prior abdominal/pelvic surgery on the complication rate of patients treated with radiation therapy for cancer of the uterine cervix. Presented at the 64th annual meeting of the American Radium Society, San Diego, CA. March, 1982.
3. Kim RY, Levy DS, Bracho DJ, **Hatch KD**. Uterine perforation during intracavitary application: Its management and results in carcinoma of the cervix. Presented at the 68th annual meeting of the Radiological Society of North America. November, 1982.
4. **Hatch KD**, Parham G, Shingleton HM, Austin Jr. JM, Orr Jr. JW. Ureteral strictures and fistulae following radical hysterectomy. To be published in: International Synopses Periodical.
5. McGuire W, Blessing J, Stehman F, **Hatch KD**. Phase II study of CHIP in advanced squamous cell carcinoma of the cervix. For the Gynecologic Oncology Group (GOG). ASCO, #C-472. March, 1985.
6. Arseneau JC, **Hatch KD**, Stehman F, Blessing J. Phase II study of carboplatinum in advanced squamous cell carcinoma of the cervix. For the Gynecologic Oncology Group (GOG). ASCO, #C-468. March, 1985.
7. **Hatch KD**, Bart B, Hansen R, Millikan L, Reichman R, Berman B. Evaluation of Interferon Alpha-2 in the treatment of condyloma acuminatum. Presented at the 14th International Congress of Chemotherapy, Kyoto, Japan. June 23-28, 1985.
8. **Hatch KD**, Bart B, Hansen R, Reichman R. Evaluation of Interferon Alpha-2 in the treatment of condyloma acuminatum. Presented at the Eighth World Congress of the International Society for the Study of Vulvar Disease, Mariehamn, Finland. September, 1985.
9. **Hatch KD**, Bart B, Hansen R, Reichman R. Evaluation of Interferon Alpha-2 in the treatment of condyloma acuminatum. Presented at the XIth World Congress of Gynecology and Obstetrics, West Berlin, Germany - September 1985. Published in: Archives of Gynecology Vol. 237 (Supplement), September 1985.
10. **Hatch KD**, Shingleton HM, Orr Jr. JW. Reconstructive surgical techniques following radical vulvectomy. Presented at the Society of Pelvic Surgeons in Miami, FL. November, 1985.

11. **Hatch KD**, Hedayat MM, Khazeali MB, Shingleton HM, To ACW, Boots LR, Orr Jr. JW, LoBuglio AF. A new beta HCG assay for early detection of persistent gestational trophoblastic disease. Presented at the Society of Gynecologic Oncologists Meeting in Miami, FL. February, 1986.
12. Tying SK, Cauda R, Grossi C, Tilden AB, Sams Jr. WM, **Hatch KD**, Baron S, Whitley RJ: Peripheral blood mononuclear cells from patients with condyloma acuminatum exhibit decreased Interleukin 2 and Interferon Gamma production and depressed natural killer activity. Presented at the Federation of American Society for Experimental Biology Meeting, St. Louis, MO. April 13-18, 1986.
13. Alvarez RD, To A, Boots LR, Shingleton HM, **Hatch KD**, Hubbard J, Soong S-J. CA125 as an indicator for poor prognosis in ovarian cancer. Presented at the ACOG Annual District VII Meeting, Little Rock, AR. October 11-15, 1986.
14. Holloway RW, To ACW, Boots LR, Shingleton HM, **Hatch KD**, Soong S-J. Serum SCC titers as prognostic indicator in squamous cell carcinoma of the cervix. Presented at the ACOG Annual District VII Meeting, Little Rock, AR. October 11-15, 1986.
15. **Hatch KD**. Low resection and anastomosis in radical pelvic surgery. Presented at the Society of Pelvic Surgeons Meeting, Newport Beach, CA. November, 1986.
16. Potter ME, Baker VV, **Hatch KD**, Alvarez RD, Soong S-J, Butterworth Jr. CE, Cole P. Cervical intraepithelial neoplasia and the human papillomavirus - the "natural" history. Presented at the Sixth International Papillomavirus Workshop, Washington, D.C. June 14-18, 1987.
17. Potter ME, Baker VV, **Hatch KD**, Alvarez RD, Soong S-J, Butterworth Jr. CE, Cole P. Human papillomavirus and associated risk factors for the development of cervical intraepithelial neoplasia. Presented at the Sixth International Papillomavirus Workshop, Washington, D.C. June 14-18, 1987.
18. **Hatch KD**. Interferon Alpha-2 (Intron-A) for HPV vaginitis and vulvitis. Presented at the International Society for the Study of Vulvar Disease, Broadbeach, Queensland, Australia. August 30 - September 4, 1987.
19. Beecham J, Blessing J, Creasman W, **Hatch KD**. Responsiveness to Tamoxifen in 107 patients treated with cytoreductive surgery and front line chemotherapy: A Gynecologic Oncology Group Study. (Abstract) 1st Meeting of the International Gynecologic Cancer Society, Amsterdam, The Netherlands. October, 1987.
20. Beecham J, Blessing J, Creasman W, **Hatch KD**. Tamoxifen responsiveness, hormone receptors and tumor grade: A prospective study of 105 advanced ovarian cancer patients. For the Gynecologic Oncology Group. (Abstract) SGO. February 7-10, 1988.

21. Baker VV, Allen DN, **Hatch KD**, Shingleton HM. Amplification of the c-myc oncogene in primary and metastatic ovarian cancer. Presented at the Society of Gynecologic Investigation Meeting, Baltimore, MD. March 17-20, 1988.
22. Potter M, **Hatch KD**, Soong S, Shingleton H, Austin J, Partridge E. Second look laparotomy in ovarian cancer. Presented at the American College of Obstetricians and Gynecologists Meeting, Boston, MA. May 2-5, 1988.
23. Khazaeli MB, Buchina ES, Pattillo RA, **Hatch KD**. Free B-subunit of human chorionic gonadotropin (hCG) in the diagnosis of high and low risk gestational trophoblastic disease. Presented at the IV World Congress on GTN. September 19-22, 1988.
24. **Hatch KD**, Baker V, Macaluso M, Cole P, Soong S, Butterworth C, Austin L. A case-control study of cervical dysplasia and HPV-16. Presented at the Third International Conference on HPV and Squamous Carcinoma, Chicago, IL. October 24-26, 1988.
25. Potter ME, **Hatch KD**, Soong S-J, Partridge EE, Austin JM, Shingleton HM. Second look laparotomy and subsequent therapy of patients with epithelial ovarian cancer. Presented at the Armed Forces District 27th Annual Meeting, San Antonio, TX. November 6-10, 1988.
26. Potter ME, **Hatch KD**, Potter MY, Shingleton HM, Baker VV. Factors affecting the response of recurrent squamous cell carcinoma of the cervix to CIS Diaminodichloro Platinum. Presented at the Armed Forces District 27th Annual Meeting, San Antonio, TX. November 6-10, 1988.
27. Potter ME, Partridge EE, **Hatch KD**, Soong S-J, Austin JM, Shingleton HM. The primary surgical therapy of ovarian cancer: How much, by whom and when. Presented at the Armed Forces District 27th Annual Meeting, San Antonio, TX. November 6-10, 1988.
28. Nicolson V, Shin M, Baker V, Shingleton H, **Hatch KD**, Potter M: Varied appearances of pulmonary metastases in squamous cell carcinoma of the cervix. Presented at the Society of Gynecologic Oncologists Meeting, Maui, Hawaii. February 5-9, 1989.
29. Weppelmann B, **Hatch KD**, Soong S-J, Kim RY, Shingleton HM, Salter MM. Stage I cancer of the endometrium - Risk factors, patterns of failure and therapeutic implications. To be presented at the American Society of Radiation Oncology, San Francisco, CA. October, 1989.
30. Kim RY, Salter MM, Soong S-J, Weppelmann B, Spencer SA, Meredith RF, **Hatch KD**. Cancer of the uterine cervix: Impacts of conservative radiation treatment of local failure and survival. Presented at the 2nd Meeting of The International Gynecologic Cancer Society, Toronto, Canada. October, 1989.

31. Alberts D, Miranda E, Dorr R, Nichols N, Ketcham M, Macneal W, **Hatch KD**, Surwit E, Childers J, Taylor C, Ahmann R, Salmon S. Phase II and Pharmacokinetic (PK) and Human Tumor Cloning Assay (HICA) Study of Suramin in Advanced Ovarian Cancer (1990).
32. Thigpen T, Blessing J, **Hatch KD**, Barrett M, Adelson P, Disaia P. A randomized trial of Medroxyprogesterone Acetate (MPA) 200 MG versus 1000 MG daily in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study, ASCO 1991;10:185 Abstr. #604.
33. **Hatch, KD**. Neo-vaginal reconstruction. Presented at American Cancer Society National Conference on Gynecologic Cancers, Orlando, FL. April 2-4, 1992.
34. Childers JM, Surwit EA, **Hatch KD**. Laparoscopic and vaginal surgery for the management of endometrial cancer. Western Association of Gynecologic Oncologists Meeting, Durango, Colorado. June, 1992.
35. Childers JM, Surwit EA, **Hatch KD**. Office laparoscopy under local anesthesia for patients with intraperitoneal malignancies. Western Association of Gynecologic Oncologists Meeting, Durango, Colorado. June, 1992.
36. Childers JM, Surwit EA, **Hatch KD**. The safety and efficacy of laparoscopic para-aortic lymphadenectomy in gynecologic malignancies. Western Association of Gynecologic Oncologists Meeting, Durango, Colorado. June, 1992.
37. PengYM, PengYS, Childers JM, **Hatch KD**, LinY, Baier M, Roe DJ. Concentrations and plasma-tissue relationship of carotenoids, retinoids and tocopherols in patients with cancer, cervical dysplasia and other abnormalities. American Assoc. for Cancer Research; 1994.
38. Guiliano A, Schneider A, Lee H, Nour MA, Webb-Jernigan B, **Hatch KD**. Relationship of High Risk Type HPV infection and Cervical Dysplasia (SIL) to Serum Nutrient Concentrations. Scientific Presentation at the 13th International Papillomavirus Conference in Amsterdam, The Netherlands. October 1994.
39. Surwit E, Childers J, Hallum III A, Nour MA, **Hatch KD**. Neoadjuvant Chemotherapy in Advanced Ovarian Cancer. Scientific talk presented at the 25th Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, California February 1995 and submitted for publication in Gynecologic Oncology Journal; 1995.
40. Short B, Giuliano A, Piyashilako C, Nour M, **Hatch KD**. Hypomethylation An Early Event in Cervical Carcinogenesis. Presented at the 21st Annual Meeting in New Orleans, Louisiana. March 23-25, 1997.

41. **Hatch KD.** Laparoscopic Radical Vaginal Hysterectomy (Shauta) and Nodal Dissection. Society of Gynecologic Oncologists – Poster Presentation; 1997
42. **Hatch, KD.** Treatment of Vaginal Intraepithelial Neoplasia and Vaginal Cancer. Proceedings of ISSVD, Baveno, Italy. September 1997.
43. **Hatch, KD.** Radical Hysterectomy by Laparoscopy. Presented at the Wertheim Meeting in Vienna, Austria. 1998.
44. Anderson J, Nguyen T, Hallum AV, Childers J, Surwit E, **Hatch KD**, Rogoff E, Stea B. High dose rate post-operative vaginal cuff irradiation alone for Stage I endometrial cancer with myometrial invasion. Proceedings of the American Society for Therapeutic Radiology and Oncology, 40<sup>th</sup> Annual Meeting; 1999.
45. **Hatch KD.** Management of endometrial cancer by laparoscopy. Society of Gynecologic Oncologist of Argentina; 1999.
46. Garcia FAR, Guiliano A, **Hatch KD**, Baldwin S, Mendez E, Denman C, Gurnsey J, Papenfuss M, Stephens J, Abramson M. Preliminary Results of the Bi-National Human Papilloma Virus Study. Presented at ASCCP 2000 Biennial Meeting; 2000.
47. Alberts DS, Hallum A, **Hatch KD**, Stratton-Custis M, Carrier A, et al. Phase I and pharmacokinetic studies of APOMINE (SR-45023A), a novel, oral anticancer drug. Submitted to AACR, 2001.
48. Garcia F, Davis J, Alberts D, **Hatch KD**, Weyn B, Thompson D, Bartels P. NuclearChromatin Patterns in Normal, Hyperplastic and Atypical Endometrium. AQCH Abstracts. July 2001.
49. **Hatch, KD.** Laparoscopic assisted vaginal hysterectomy and total abdominal hysterectomy for the treatment of endometrial carcinoma and analysis of recurrent rates over thirty-three months: A retrospective cohort study. Gynecologic Oncology Volume 94. Abstract 228. 2004.
50. **Hatch, KD.** Evaluation of Guidelines for referral of adnexal mass. Society of Gynecologic Oncologist. Abstract 56. Presented at San Diego, CA. Feb. 10, 2004.
51. **Hatch, KD.** Stanley Lecture, Columbus, GA. Nov. 18, 2005.
52. **Hatch KD.** New Developments in Cervical Cancer: A Promise for Prevention? Society of Gynecologic Oncologists Annual Meeting, Miami Beach, FL, March 20, 2005.
53. **Hatch KD.** Minimally invasive Surgery—Preserving Fertility in Young Women with Cancer. 37<sup>th</sup> Annual Tucson Seminar Focus on Women’s Cancer, Tucson, AZ, Jan 27, 2006.



**VIDEO**

Bishop M, Hatch KD, et al. Comprehensive Education in Palliative/End-of-life Care (CEPEC) for Hospice Model of Care Program for 2<sup>nd</sup> year medical students at University of Arizona.

Beginning Spring 2006.